Jazz Pharmaceuticals (NASDAQ: JAZZ) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.
Volatility & Risk
Jazz Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Affymax has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Jazz Pharmaceuticals and Affymax, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jazz Pharmaceuticals currently has a consensus price target of $181.95, indicating a potential upside of 19.36%. Given Jazz Pharmaceuticals’ higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Affymax.
Insider & Institutional Ownership
90.3% of Jazz Pharmaceuticals shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Affymax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Jazz Pharmaceuticals and Affymax’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jazz Pharmaceuticals||$1.62 billion||5.63||$487.84 million||$7.96||19.15|
Jazz Pharmaceuticals has higher revenue and earnings than Affymax.
This table compares Jazz Pharmaceuticals and Affymax’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Jazz Pharmaceuticals beats Affymax on 8 of the 9 factors compared between the two stocks.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Affymax Company Profile
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.